|
pubmed:abstractText |
A single high oral dose of 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2, 4-pyrimidinedione (FD-1) (486.0-729.0 mg/kg) followed by daily administration of lower doses of FD-1 (121.5 mg/kg) for 2-4 weeks increased the concentration of striatal dopamine (DA) in rats. The decrease in striatal DA following an injection of alpha-methyl-p-tyrosine methyl ester (alpha-MT) was lessened by a dose of FD-1 (364.8 mg/kg, p.o.) given immediately before the alpha-MT. This may indicate a decrease in striatal DA utilization by FD-1. The increase in striatal DA after FD-1 was inhibited by two antagonists of gamma-aminobutyric acid (GABA) which act on postsynaptic receptors: bicuculline (0.5-2.0 mg/kg, i.p.) and picrotoxin (2.0 mg/kg, i.p.). The increase of DA induced by the GABA transaminase inhibitor aminooxyacetic acid (AOAA) was enhanced by FD-1. These results suggest that the action of FD-1 is mediated by GABA. FD-1 probably causes inhibition of DA release from nerve terminals resulting in an accumulation of DA in the corpus striatum.
|
